Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | FDPS | P14324 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6245092 | 0.82 | GAA (1.00) | GAANPC1RAB9APKMHDAC3 | |
| SCHEMBL12446562 | 0.79 | GAA (0.58) | GAANPC1RAB9APKMHDAC3 | |
| SCHEMBL4491035 | 0.79 | GAA (0.79) | GAANPC1RAB9APKMHDAC3 | |
| SCHEMBL7006640 | 0.79 | GAA (0.79) | GAANPC1RAB9APKMHDAC3 | |
| SCHEMBL8285860 | 0.77 | GAA (0.76) | GAANPC1RAB9APKMHDAC3 | |
| SCHEMBL22281652 | 0.77 | GAA (0.76) | GAANPC1RAB9APKMHDAC3 | |
| SCHEMBL1185012 | 0.77 | GAA (0.76) | GAANPC1RAB9APKMHDAC3 | |
| SCHEMBL12426307 | 0.77 | GAA (0.82) | GAANPC1RAB9APKMHDAC3 | |
| SCHEMBL1430541 | 0.77 | GAA (0.76) | GAANPC1RAB9APKMHDAC3 | |
| SCHEMBL318557 | 0.77 | GAA (0.76) | GAANPC1RAB9APKMHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197524-A1 | Fluorenes and carbazoles as ligands of the EP2 receptor | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-08-23 | — | — | US | claimed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-9139613-B2 | Macrocyclic compounds and methods for their production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-09-22 | — | — | US | disclosed |
| EP-2691413-B1 | MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-12-24 | — | — | EP | disclosed |
| US-20140234414-A1 | Novel Dosage Form | Abliva Ab (SE) | 2014-08-21 | — | — | US | disclosed |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | JIANG TAO | 2009-07-30 | — | — | US | disclosed |
| US-20080015195-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | METABASIS THERAPEUTICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7312219-B2 | Heteroaromatic inhibitors of fructose 1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20040058892-A1 | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase | DANG QUN (US) | 2004-03-25 | — | — | US | disclosed |
| EP-1112275-B9 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS INC (US) | 2004-03-10 | — | — | EP | disclosed |
| EP-1112275-B1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS INC (US) | 2003-07-30 | — | — | EP | disclosed |
| US-6489476-B1 | FRUCTOSE-1,6-BISPHOSPHATASE ENZYME INHIBITORS ARE USEFUL IN THE TREATMENT OF DIABETES AND OTHER CONDITIONS ASSOCIATED WITH ELEVATED BLOOD GLUCOSE OR EXCESS GLYCOGEN STORAGE. | METABASIS THERAPEUTICS, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. | 2002-11-21 | — | — | US | disclosed |
| EP-1143955-A3 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1143955-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1112275-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | Metabasis Therapeutics, Inc. (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000038666-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000014095-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058892-A1 | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase | FBP1, G6PC1, HK1 | GAA 169/4885NPC1 1974/4885RAB9A 3842/4885 |
| US-20080015195-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | FBP1, ALDOA, G6PC1 | GAA 163/4885NPC1 1907/4885RAB9A 3647/4885 |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, G6PC1 | GAA 333/4885NPC1 1604/4885RAB9A 1895/4885 |
| US-20140234414-A1 | Novel Dosage Form | SI, RAB10, SAMM50 | GAA 835/4885NPC1 2190/4885RAB9A 142/4885 |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | FBP1, PFKFB1, PFKFB2 | GAA 246/4885NPC1 2241/4885RAB9A 1770/4885 |
| US-20070197524-A1 | Fluorenes and carbazoles as ligands of the EP2 receptor | PTGER2, PTGER1, PTGDR2 | GAA 4818/4885NPC1 1301/4885RAB9A 2665/4885 |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | HAVCR2, RPL35, CD4 | GAA 1603/4885NPC1 484/4885RAB9A 3175/4885 |
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | FBP1, G6PC1, IRS1 | GAA 74/4885NPC1 2827/4885RAB9A 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.